Effects of a multidomain intervention against cognitive decline on dementia risk profiles - Results from the AgeWell.de trial
- PMID: 38967275
- PMCID: PMC11350131
- DOI: 10.1002/alz.14097
Effects of a multidomain intervention against cognitive decline on dementia risk profiles - Results from the AgeWell.de trial
Abstract
Introduction: Dementia risk scores constitute promising surrogate outcomes for lifestyle interventions targeting cognitive function. We investigated whether dementia risk, assessed using the LIfestyle for BRAin health (LIBRA) index, was reduced by the AgeWell.de intervention.
Methods: Secondary analyses of the AgeWell trial, testing a multicomponent intervention (including optimization of nutrition, medication, and physical, social, and cognitive activity) in older adults with increased dementia risk. We analyzed data from n = 461 participants with complete information on risk/protective factors comprised by LIBRA at the 24-month follow-up. Intervention effects on LIBRA and LIBRA components were assessed using generalized linear models.
Results: The intervention reduced LIBRA scores, indicating decreased dementia risk at follow-up (b = -0.63, 95% confidence interval [CI]: -1.14, -0.12). Intervention effects were particularly due to improvements in diet (odds ratio [OR]: 1.60, 95% CI: 1.16, 2.22) and hypertension (OR: 1.61, 95% CI: 1.19, 2.18).
Discussion: The AgeWell.de intervention reduced dementia risk. However, several risk factors did not improve, possibly requiring more intensive interventions.
Highlights: The AgeWell.de intervention reduced dementia risk according to LIfestyle for BRAin health (LIBRA) scores. Beneficial effects on LIBRA are mainly due to changes in diet and blood pressure. A pragmatic lifestyle intervention is apt to reduce dementia risk in an at-risk population.
Keywords: dementia; lifestyle; prevention; randomized controlled trial; risk factor.
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Conflict of interest statement
The authors declare that they have no competing interests. Author disclosures are available in the supporting information.
References
-
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388:9‐21. - PubMed
-
- Mintun MA, Lo AC, Duggan EC, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384:1691‐1704. - PubMed
-
- Kumari S, Bagri K, Deshmukh R. Chapter 2 ‐ Dementia: a journey from cause to cure. In: Gupta U, Kesharwani P, eds. Nanomedicine‐Based Approaches for the Treatment of Dementia. Academic Press; 2023:37‐56. doi:10.1016/B978-0-12-824331-2.00011-X - DOI
Publication types
MeSH terms
Grants and funding
- 01GL1704A/German Federal Ministry for Education and Research
- 01GL1704B/German Federal Ministry for Education and Research
- 01GL1704C/German Federal Ministry for Education and Research
- 01GL1704D/German Federal Ministry for Education and Research
- 01GL1704E/German Federal Ministry for Education and Research
LinkOut - more resources
Full Text Sources
Medical
